Literature DB >> 31446853

Workload of breast image-guided intensity-modulated radiotherapy delivered with TomoTherapy.

Rosalinda Ricotti1, Eleonora Miglietta1, Maria Cristina Leonardi1, Federica Cattani2, Samantha Dicuonzo1, Damaris Patricia Rojas1, Giulia Marvaso1, Roberto Orecchia3, Barbara Alicja Jereczek-Fossa1,4.   

Abstract

OBJECTIVE: To report treatment times (door to door) of adjuvant treatments of breast cancer (BC) with intensity-modulated radiotherapy (IMRT).
METHODS: Treatment times of 62 patients with BC on the TomoTherapy Hi-Art System were collected for the analysis. Patients underwent either locoregional radiotherapy (postmastectomy radiotherapy [PMRT]) with helical modality (TomoHelical) or whole breast radiotherapy (RT) with simultaneous integrated boost (WBRT-SIB) with direct modality (TomoDirect). Door-to-door time was broken down into different steps, which were crucial to RT session.
RESULTS: A total of 594 treatment fractions were monitored. Median treatment time was 22.4 minutes (17.2-30.8) for PMRT and 14.4 minutes (10.9-23.5) for WBRT-SIB. The mean beam-on time accounted for 61.36% of the overall treatment time for PMRT compared to 57% for WBRT-SIB. The beam-on time was a much more time-consuming process.
CONCLUSION: This treatment times analysis on the use of IMRT for BC might be useful to organize and improve the workflow efficiency in RT facilities.

Entities:  

Keywords:  TomoTherapy; adjuvant radiotherapy; breast cancer; treatment time

Mesh:

Year:  2019        PMID: 31446853     DOI: 10.1177/0300891619868014

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  1 in total

1.  Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: prospective series of 287 early breast cancer patients.

Authors:  S Dicuonzo; M C Leonardi; D P Rojas; B A Jereczek-Fossa; S Raimondi; G Corrao; V Bagnardi; M A Gerardi; A Morra; M A Zerella; M Zaffaroni; F Pansini; F Cattani; R Luraschi; C Fodor; P Veronesi; R Orecchia
Journal:  Clin Transl Oncol       Date:  2021-02-03       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.